JCR Pharmaceuticals Co.,Ltd. [4552.T]
TOKYO, Jun 23 (Pulse News Wire) – JCR Pharmaceuticals CO.,LTD. (4552.T) disclosed that its major shareholder, Medipal Holdings Co., Ltd., owns 23.86% of its shares.
Medipal Holdings, listed on the Tokyo Stock Exchange Prime Market, is considered an associated company of JCR Pharma. In June 2026, JCR Pharma entered into a business capital alliance agreement with Medipal Holdings to leverage their respective strengths—Medipal's logistics and sales capabilities and JCR Pharma’s drug development expertise—to enhance corporate value and sustainable growth. Additionally, in October 2022, JCR Pharma signed memorandums granting exclusive negotiation rights for four drug candidates targeting ultra-rare lysosomal diseases outside Japan, along with licensing agreements for treatments targeting mucopolysaccharidosis IIIB and GM2 gangliosidosis.
Regarding operational activities and management decisions, JCR Pharma operates independently under its own responsibility. Notably, Ito Shunhei serves as an external director and concurrently holds positions as the head of the Business Development Department and IR officer at Medipal Holdings and as a director at JCR USA, Inc. No significant transactions involving related parties were reported.
🟢 Confidence: High AI-translated content.